Ophthalmology Medical Science Liaison & Field Advisor

Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Our company was the first to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018, iStent inject® W in September 2020, and iStent infinite® in 2022. In late 2023, the iDose TR® (travoprost intracameral implant) 75 mcg procedural pharmaceutical received FDA approval with a commercial launch commencing in 2024. On the corneal health front, our company is the maker of the first and only FDA-approved cross-linking technology for progressive keratoconus, a degenerative, sight-threatening corneal disorder. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases. Glaukos Corporation is an Equal Opportunity Employer If you are an individual with a disability and/or would like to request a reasonable accommodation as part of the employment application process, please email HR@Glaukos.com or call direct at 949-367-9600 and ask to speak with a member of the Talent Acquisition team. Glaukos Corporation is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex including sexual orientation and gender identity, national origin, disability, protected Veteran Status, or any other characteristic protected by applicable federal, state, or local law.

#J-18808-Ljbffr